Knowledge Nugget of the day: Patent evergreening
What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...
Seeking Alpha2d
Gilead Sciences: Finally Some Real Momentum
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...
Gilead price target raised to $95 from $85 at TD Cowen
TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...
Gilead cut to Hold at Maxim on valuation
Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...
Hosted on MSN5d
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week. The remaining ...
Zacks.com on MSN7d
Gilead Science to Report Q3 Earnings: What's in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The ...
The Financial Express13d
Dr. Reddy’s launches first-in-class drug to treat chronic constipation in India
Dr. Reddy’s Laboratories Ltd. on Monday announced the launch of Elobixibat, a first-in-class drug to treat chronic ...
kalkinemedia17d
Tectonic Advisors LLC Secures 9,958 Shares in Gilead Sciences, In...
Highlights,Tectonic Advisors LLC increased its position in Gilead Sciences, Inc. by 15.1% during the third ...
Nasdaq20d
Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $ ...